Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.51 |
| ▸ | XDH | P47989 | 2/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14428679 | 0.99 | ESR1 (0.58) | ESR1ESR2XDH | |
| SCHEMBL14428684 | 0.91 | ESR1 (0.57) | ESR1ESR2XDH | |
| SCHEMBL5426736 | 0.90 | ESR1 (0.57) | ESR1 | |
| SCHEMBL5416855 | 0.90 | ESR1 (0.54) | ESR1ESR2XDH | |
| SCHEMBL5417604 | 0.90 | ESR1 (0.54) | ESR1ESR2XDHF2 | |
| SCHEMBL4621596 | 0.89 | ESR1 (0.55) | ESR1ESR2XDH | |
| SCHEMBL4619222 | 0.89 | ESR1 (0.55) | ESR1ESR2XDH | |
| SCHEMBL6810576 | 0.89 | ESR1 (0.68) | ESR1ESR2F2 | |
| Hydrochloric Acid SCHEMBL5417631 | 0.88 | ESR1 (0.67) | ESR1ESR2F2 | |
| SCHEMBL4641975 | 0.88 | ESR1 (0.68) | ESR1ESR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040882-A1 | USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS | NOVARTIS AG (CH) | 2013-02-14 | — | — | US | disclosed |
| US-20120028896-A1 | USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS | NOVARTIS AG | 2012-02-02 | — | — | US | disclosed |
| EP-1682665-B1 | USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS | NOVARTIS AG (CH) | 2011-04-27 | — | — | EP | disclosed |
| US-20090093398-A1 | Use of Fibroblast Growth Factor Fragments | BOLLEKENS JACQUES | 2009-04-09 | — | — | US | disclosed |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | MCKIE JEFFREY A | 2007-01-18 | — | — | US | disclosed |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | MCKIE JEFFREY A | 2007-01-18 | — | — | US | disclosed |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | MCKIE JEFFREY A | 2007-01-18 | — | — | US | disclosed |
| US-20040092572-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | NOVARTIS AG (CH) | 2004-05-13 | — | — | US | disclosed |
| US-6620838-B1 | Anticarcinogenic, antimestasis, and antiarthritic agents; osteoporosis and endometriosis treatment | SIGNAL PHARMACEUTICALS, INC. | 2003-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093398-A1 | Use of Fibroblast Growth Factor Fragments | FGF2, FGF23, FGF1 | ESR1 3960/4885ESR2 3255/4885XDH 3837/4885 |
| US-20120028896-A1 | USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS | FGF2, FGF23, FGF1 | ESR1 3893/4885ESR2 3218/4885XDH 3898/4885 |
| US-20070015817-A1 | 4-((4-(2-pyrrolidinylethoxy)phenyl)methyl)-3-(4-(trifluoromethyl)phenyl)-7-hydroxychromen-2one, pharmaceutically acceptable salts thereof and methods of use therewith | ESR2, CYP19A1, ESRRA | ESR1 4/4885ESR2 1/4885XDH 1577/4885 |
| US-20130040882-A1 | USE OF FIBROBLAST GROWTH FACTOR FRAGMENTS | FGF2, FGF23, FGF1 | ESR1 3960/4885ESR2 3255/4885XDH 3837/4885 |
| US-20040092572-A1 | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | ESR2, ESRRA, ESR1 | ESR1 3/4885ESR2 1/4885XDH 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.